Literature DB >> 25782318

[Orthostatic reactions in prognosis of the risks of arterial hypertension as a component of metabolic syndrome].

T L Olenskaia, N Iu Konevalova, S I Rapoport, K I Proshchaev, K L Kozlov, G D Korobov.   

Abstract

It was shown that parameters of metabolic syndrome as predictors of lethal vascular outcomes of arterial hypertension (AH) in Belarus are significantly different fiom those proposed in WHO recommendations (1999). The glucose level of informative value in WHO recommendations is 6.1 mmol/l versus 5.6 mmol/l in Belarus, total cholesterol 5.0 and 5.9 mmol/l respectively. A more detailed verification of the value of both parameters is needed for the patients in Belarus and Russia depending on age and sex using non-linear models. We used a comprehensive approach to prognosis of the risk of vascular lethal outcomes of AH as a component of metabolic syndrome with the evaluation of results of clinical and laboratory examination as well as orthostatic reactions in patients of different age groups. Construction of the prognostic algorithm "Classification tree" taking account of orthostatic reactions enhances the correctness of lethal outcome prognosis up to 81.8%. The study revealed the prognostic value of systolic and diastolic arterial pressure in the supine position (15 min of active aortostatic sample) for prognostication of vascular lethal outcomes. Further studies are needed on the role of orthostatic reactions in AH patients of old age together with clinical and laboratory parameters in the prognostication of outcomes of various cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25782318

Source DB:  PubMed          Journal:  Klin Med (Mosk)        ISSN: 0023-2149


  1 in total

1.  Prevalence of orthostatic hypertension and its association with cerebrovascular diagnoses in patients with suspected TIA and minor stroke.

Authors:  Farzaneh Barzkar; Phyo K Myint; Chun Shing Kwok; Anthony Kneale Metcalf; John F Potter; Hamid Reza Baradaran
Journal:  BMC Cardiovasc Disord       Date:  2022-04-09       Impact factor: 2.298

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.